Although rare overall, choroidal melanoma is the most common intraocular cancer in adults, with an incidence of approximately 11,000 patients per year in the United States and Europe. The standard of care remains radiotherapy, which frequently results in irreversible vision loss. There are no FDA-approved therapies for choroidal melanoma.
The company we are profiling today is Aura Biosciences Inc. (AURA), whose lead drug candidate is in a global phase 3 trial for the first-line treatment of early-stage choroidal melanoma.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com